Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta (+44% cc), Pluvicto (+45% cc) and Scemblix (+95% cc) Core operating income margin 1 was ...
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...
Explore opportunities with Novartis below.
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
Our leaders in Indonesia are experienced professionals, both in global and local pharmaceutical industry.
Atklājiet darba iespējas Novartis. Lai atrastu papildu Novartis Gene Therapies (agrāk AveXis) darba piedāvājumus, apmeklējiet GTx karjeras meklēšanas lapu ...
背景 抗癌剤治療をしながら働き続ける私に、上司が言った言葉。凄く矛盾してて日本語になってないけれど、体調を気遣ってくれる気持ちと、働き続けようとする私の気持ちを汲んで応援し ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback